A Phase III Randomized Multinational Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT 1, GT 4 and GT 6 Infection
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms C-CORAL
- Sponsors Merck Sharp & Dohme
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2016.
- 21 Apr 2016 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History